Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
The CD38-targeting antibody daratumumab mediates its anti-myeloma activities not only through Fc-receptor-dependent effector mechanisms, but also by its effects on T-cell immunity through depletion of CD38<sup>+</sup> regulatory T-cells, regulatory B-cells, and myeloid-derived suppressor...
Main Authors: | Christie P. M. Verkleij, Amy Jhatakia, Marloes E. C. Broekmans, Kristine A. Frerichs, Sonja Zweegman, Tuna Mutis, Natalie A. Bezman, Niels W. C. J. van de Donk |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/12/3713 |
Similar Items
-
PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression
by: Federica Costa, et al.
Published: (2021-01-01) -
Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80
by: Kaniel Cassady, et al.
Published: (2018-12-01) -
Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01) -
Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy
by: Panagiotis Balermpas, et al.
Published: (2017-03-01) -
Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
by: Miren Zuazo, et al.
Published: (2020-11-01)